Sulfasalazin (SAS) is an inhibitor of the glutamate-cystine exchanger xCT and was therefore regarded as a potential anti-tumor drug, counteracting glutamate release by glioma cells [34,131]. This evidence concerns the gene SLC7A11 and glioma.